The difference in all-cause mortality between COVID-19 patients treated with standard of care plus placebo and those treated with standard of care alone: a network meta-analysis of randomised controlled trials of immunomodulatory kinase inhibitors

Tseng, Ping-TaoPing-TaoTsengZeng, Bing-SyuanBing-SyuanZengHsu, Chih-WeiChih-WeiHsuThompson, TrevorTrevorThompsonStubbs, BrendonBrendonStubbsPO-REN HSUEHSu, Kuan-PinKuan-PinSuChen, Yen-WenYen-WenChenChen, Tien-YuTien-YuChenWu, Yi-ChengYi-ChengWuLin, Pao-YenPao-YenLinCarvalho, Andre FAndre FCarvalhoLi, Dian-JengDian-JengLiYeh, Ta-ChuanTa-ChuanYehSun, Cheuk-KwanCheuk-KwanSunCheng, Yu-ShianYu-ShianChengShiue, Yow-LingYow-LingShiueLiang, Chih-SungChih-SungLiangYU-KANG TU2024-02-072024-02-072024-0201410768https://scholars.lib.ntu.edu.tw/handle/123456789/639683The aim of this network meta-analysis (NMA) was to assess whether participants assigned to a placebo and standard of care (SoC) group had different major coronavirus disease 2019 (COVID-19)-related outcomes than those assigned to SoC alone.enCOVID-19; Network meta-analysis; immunomodulatory kinase inhibitor; mortality; placeboThe difference in all-cause mortality between COVID-19 patients treated with standard of care plus placebo and those treated with standard of care alone: a network meta-analysis of randomised controlled trials of immunomodulatory kinase inhibitorsjournal article10.1177/01410768231202657379714122-s2.0-85177480371https://api.elsevier.com/content/abstract/scopus_id/85177480371